Publications by authors named "J A Weisman"

Remediation of preclinical course failures in the DVM program at Purdue University College of Veterinary Medicine began in 2010. We set out to understand whether some students were more likely than others to use remediation opportunities and succeed. Student demographics, undergraduate (UG) experiences, including institution attended and major studied, UG performance as measured by grade point average (uGPA), and extent of academic difficulties in DVM years 1-3 were studied at univariate levels to determine which students more often failed ≥1 courses, remediated ≥1 courses, and were successful in all remediation attempts.

View Article and Find Full Text PDF

Remediation provides academically struggling students reasonable opportunities to correct deficiencies in knowledge or skills, achieve competence, and potentially reverse failures. At Purdue University College of Veterinary Medicine, a remediation policy in the preclinical years of the DVM program was implemented beginning with the class of 2014. We evaluated its impact on our DVM program and student outcomes.

View Article and Find Full Text PDF
Article Synopsis
  • Atopic dermatitis (AD) is a chronic skin condition with few treatment options for teens, and lebrikizumab, an antibody targeting IL-13, shows potential benefits in treating it, based on previous studies.
  • The Phase 3 ADore study involved 206 adolescents with moderate-to-severe AD, who received lebrikizumab and were monitored for safety and effectiveness over 52 weeks.
  • Out of 172 participants who completed the study, many experienced improvements, such as 65% achieving significant reductions in disease severity, while serious side effects were infrequent, indicating the treatment's promise for managing AD in adolescents.
View Article and Find Full Text PDF

Introduction: Hidradenitis suppurativa (HS) is a chronic, debilitating, and painful inflammatory skin disease that significantly and negatively impacts patients' quality of life. The prevalence of HS in the USA is estimated to be 0.10%, with worldwide reports suggesting a prevalence closer to 1%.

View Article and Find Full Text PDF